Quantum Genomics Société Anonyme announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States (CIS) and Turkey. Julphar will receive exclusive rights to manufacture and market firibastat in the following geographic areas: the MENA1 region, CIS2, Turkey and all other countries on the African continent. With its manufacturing facilities in the emirate of Ras Al Khaimah, making it possible to mass produce firibastat, Julphar will also be Quantum Genomics’ exclusive supplier for said regions. Quantum Genomics will receive up to $20M in upfront, development and sales milestone payments as well as royalties on future firibastat sales.